Search results for "indoles"

showing 10 items of 251 documents

New Tripentone Analogs with Antiproliferative Activity

2017

Tripentones represent an interesting class of compounds due to their significant cytotoxicity against different human tumor cells in the submicro-nanomolar range. New tripentone analogs, in which a pyridine moiety replaces the thiophene ring originating the fused azaindole system endowed with anticancer activity viz 8H-thieno[2,3-b]pyrrolizinones, were efficiently synthesized in four steps with fair overall yields (34–57%). All tripentone derivatives were tested in the range of 0.1–100 μM for cytotoxicity against two human tumor cell lines, HCT-116 (human colorectal carcinoma) and MCF-7 (human breast cancer). The most active derivative, with GI50 values of 4.25 µM and 20.73 µM for HCT-116 a…

8H-thieno[23-b]pyrrolizinonePyridinesPharmaceutical SciencetripentonesApoptosis01 natural sciencesAnalytical Chemistrychemistry.chemical_compoundDrug DiscoveryThiopheneCytotoxic T cellCytotoxicityMolecular StructureCell Cycletripentoneproapoptotic agentsCell cycleBiochemistryChemistry (miscellaneous)MCF-7 CellsMolecular Medicineaza-indolesAntineoplastic Agents010402 general chemistryArticlelcsh:QD241-441Structure-Activity Relationshiplcsh:Organic chemistryCell Line TumormedicineHumansantitumor activityPhysical and Theoretical ChemistryMode of actionCell ProliferationDose-Response Relationship Drug010405 organic chemistryOrganic ChemistryCancermedicine.diseaseHCT116 CellsSettore CHIM/08 - Chimica Farmaceutica0104 chemical sciences8H-thieno[23-b]pyrrolizinoneschemistryApoptosisCell cultureaza-indoletripentones; aza-indoles; 8<i>H</i>-thieno[23-<i>b</i>]pyrrolizinones; antitumor activity; proapoptotic agentsCaco-2 CellsMolecules; Volume 22; Issue 11; Pages: 2005
researchProduct

ANNELATED ISOINDOLES WITH POTENT ANTITUMOR ACTIVITY

2009

ANNELATED ISOINDOLESSettore CHIM/08 - Chimica Farmaceutica
researchProduct

New prospective in treatment of Parkinson's disease: Studies on permeation of ropinirole through buccal mucosa

2012

The aptitude of ropinirole to permeate the buccal tissue was tested using porcine mucosa mounted on Franz-type diffusion cells as ex vivo model. Drug permeation was also evaluated in presence of various penetration enhancers and in iontophoretic conditions. Ropinirole, widely used in treatment of motor fluctuations of Parkinson's disease, passes the buccal mucosa. Flux and permeability coefficient values suggested that the membrane does not appear a limiting step to the drug absorption. Nevertheless, an initial lag time is observed but the input rate can be modulated by permeation enhancement using limonene or by application of electric fields. Absorption improvement was accompanied by the …

Absorption (pharmacology)IndolesTime FactorsSwinePharmaceutical SciencePharmacologyModels BiologicalPermeabilityAntiparkinson AgentsBuccal delivery Ropinirole Parkinson's disease Absorption enhancement Porcine buccal mucosaDrug Delivery SystemsElectricityCyclohexenesmedicineAnimalsAdjuvants PharmaceuticIontophoresisTerpenesChemistryMouth MucosaAdministration BuccalParkinson DiseasePenetration (firestop)Buccal administrationIontophoresisPermeationRopiniroleMembraneSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoFeasibility StudiesLimoneneEx vivomedicine.drugBiomedical engineeringInternational Journal of Pharmaceutics
researchProduct

Distribution of betalain pigments in red blood cells after consumption of cactus pear fruits and increased resistance of the cells to ex vivo induced…

2005

Betalain pigments are bioavailable phytochemicals recently acknowledged as natural radical scavengers. This work, which extends previous research on the postabsorbitive fate of dietary betalains, investigated the distribution of betanin and indicaxanthin in red blood cells (RBCs) isolated from healthy volunteers (n = 8), before and during the 1-8 h interval after a cactus pear fruit meal, and the potential antioxidative activity of the pigments in these cells. A peak concentration of indicaxanthin (1.03 +/- 0.2 microM) was observed in RBCs isolated at 3 h after fruit feeding, whereas the concentration at 5 h was about half, and even smaller amounts were measured at 8 h. Indicaxanthin was no…

AdultCactaceaeMaleAntioxidantErythrocytesIndolesPyridinesmedicine.medical_treatmentBetalainsindicaxanthinred blood cellBiologyHemolysischemistry.chemical_compoundBetalainBotanymedicineHumansFood sciencecactus pear; betalains; betanin; indicaxanthin; red blood cell; oxidative hemolysis; bioavailable phytochemicalsBetaninbioavailable phytochemicalsbetaninbetalainGeneral Chemistrymedicine.diseaseHemolysisBetaxanthinsDietQuaternary Ammonium CompoundsRed blood celloxidative hemolysiKineticsmedicine.anatomical_structurechemistryCumene hydroperoxideFruitcactus pearFemaleBetacyaninsGeneral Agricultural and Biological SciencesIndicaxanthinEx vivoJournal of agricultural and food chemistry
researchProduct

Absorption, excretion, and distribution of dietary antioxidant betalains in LDLs: potential health effects of betalains in humans

2004

Background: Betalains were recently identified as natural antioxidants. However, little is known about their bioavailability from dietary sources. Objective: The objective was to evaluate the bioavailability of betalains from dietary sources. Design: The plasma kinetics and urinary excretion of betalains were studied in healthy volunteers (n 8) after a single ingestion of 500 g cactus pear fruit pulp, which provided 28 and 16 mg indicaxanthin and betanin, respectively. The incorporation of betalains in LDL and the resistance of the particles to ex vivo–induced oxidation was also researched. Results: Betanin and indicaxanthin reached their maximum plasma concentrations 3 h after the fruit me…

AdultCactaceaeMaleAntioxidantIndolesPyridinesmedicine.medical_treatmentBetalainsMedicine (miscellaneous)Biological AvailabilityAntioxidantsExcretionchemistry.chemical_compoundmedicineIngestionHumansVitamin EFood scienceChromatography High Pressure LiquidBetaninNutrition and DieteticsChemistryVitamin ECarotenebeta CaroteneBioavailabilityBetaxanthinsLipoproteins LDLQuaternary Ammonium CompoundsBiochemistryArea Under CurveFemaleBetacyaninsBetanin cactus pear dietary betalains human health indicaxanthin LDLIndicaxanthinOxidation-Reduction
researchProduct

A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematolog…

2006

Abstract Purpose: LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In this phase I study, LBH589 was administered i.v. as a 30-minute infusion on days 1 to 7 of a 21-day cycle. Experimental Design: Fifteen patients (median age, 63 years; range, 42-87 years) with acute myeloid leukemia (13 patients), acute lymphocytic leukemia (1 patient), or myelodysplastic syndrome (1 patient) were treated with LBH589 at the following dose levels (mg/m2): 4.8 (3 patients), 7.2 (3 patients), 9.0 (1 patient), 11.5 (3 patient), and 14.0 (5 patients). The levels of histone acetylation were measured using quantitative flow cytometry and plasm…

AdultCancer ResearchIndolesMaximum Tolerated Dosemedicine.drug_classApoptosisPharmacologyHydroxamic AcidsDrug Administration ScheduleHistonesStructure-Activity Relationshipchemistry.chemical_compoundPredictive Value of TestsPanobinostatAcute lymphocytic leukemiaPanobinostatBiomarkers TumormedicineHumansEnzyme InhibitorsAgedCell ProliferationAged 80 and overDose-Response Relationship Drugbusiness.industryHistone deacetylase inhibitorArea under the curveQTcF ProlongationMyeloid leukemiaMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseHypokalemiaHistone Deacetylase InhibitorsLeukemiaTreatment OutcomeOncologychemistryCinnamatesLeukemia MyeloidMyelodysplastic SyndromesAcute DiseaseInjections IntravenousImmunologymedicine.symptombusinessFollow-Up StudiesClinical Cancer Research
researchProduct

Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial

2018

Background:Gastric cancer is common malignancy and exhibits a poor prognosis. At the time of diagnosis, the majority of patients present with metastatic disease which precludes curative treatment. Non-invasive biomarkers which discriminate early from advanced stages or predict the response to treatment are urgently required. This study explored the cytokeratin-18 fragment M30 and full-length cytokeratin-18 M65 in predicting treatment response and survival in a randomized, placebo-controlled trial of advanced gastric cancer.Methods:Patients enrolled in the SUN-CASE study received sunitinib or placebo as an adjunct to standard therapy with leucovorin (Ca-folinate), 5-fluorouracil, and irinote…

AdultMale0301 basic medicineOncologymedicine.medical_specialtyIndolesmedicine.medical_treatmentLeucovorinAntineoplastic AgentsPlaceboDisease-Free SurvivalMetastasislaw.inventionPlacebos03 medical and health sciences0302 clinical medicineRandomized controlled trialStomach NeoplasmslawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorSunitinibHumansMedicinePyrrolesProgression-free survivalRC254-282AgedAged 80 and overChemotherapyKeratin-18business.industrySunitinibCancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensGeneral MedicineMiddle Agedmedicine.diseasePeptide FragmentsIrinotecan030104 developmental biology030220 oncology & carcinogenesisCamptothecinFemaleFluorouracilbusinessmedicine.drugTumor Biology
researchProduct

Lipoprotein hydrophobic core lipids are partially extruded to surface in smaller HDL: "Herniated" HDL, a common feature in diabetes

2016

AbstractRecent studies have shown that pharmacological increases in HDL cholesterol concentrations do not necessarily translate into clinical benefits for patients, raising concerns about its predictive value for cardiovascular events. Here we hypothesize that the size-modulated lipid distribution within HDL particles is compromised in metabolic disorders that have abnormal HDL particle sizes, such as type 2 diabetes mellitus (DM2). By using NMR spectroscopy combined with a biochemical volumetric model we determined the size and spatial lipid distribution of HDL subclasses in a cohort of 26 controls and 29 DM2 patients before and after two drug treatments, one with niacin plus laropiprant a…

AdultMale0301 basic medicineSimvastatinmedicine.medical_specialtyIndolesMagnetic Resonance SpectroscopySurface Properties030204 cardiovascular system & hematologyMicroscopy Atomic ForceNiacinArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFenofibrateInternal medicinemedicineHumansTriglyceridesAgedFluorescent DyesMultidisciplinaryFenofibrateCholesterolCholesterol HDLType 2 Diabetes Mellitusnutritional and metabolic diseasesLipid metabolismMiddle AgedLipid MetabolismLipids030104 developmental biologyEndocrinologyDiabetes Mellitus Type 2chemistryBiochemistryCardiovascular DiseasesSimvastatinFemalelipids (amino acids peptides and proteins)LaropiprantNiacinLipoproteinmedicine.drug
researchProduct

Roxindole, a dopamine autoreceptor agonist, in the treatment of major depression

1993

Roxindole is a potent autoreceptor-“selective” dopamine agonist originally developed for the treatment of schizophrenic syndromes. The drug also inhibits 5-HT uptake and has 5-HT1A agonistic actions. In this open clinical trial 12 in-patients suffering from a major depressive episode (DSM-III-R) were treated with roxindole for 28 days in a fixed dosage of 15 mg per day. A reduction of at least 50% in HAMD-17 total scores was observed in 8 out of 12 patients after 4 weeks (mean HAMD-17 reduction of 56% in all patients), while 4 patients did not respond to roxindole treatment. Half of the patients showed a complete psychopathological remission (HAMD-17 <8). Roxindole's onset of antidepressant…

AdultMaleAgonistIndolesPyridinesmedicine.drug_classPharmacologyDopamine agonistAsymptomaticchemistry.chemical_compoundRoxindoleDopaminemedicineHumansPharmacology (medical)Major depressive episodePsychiatric Status Rating ScalesPharmacologyDepressive Disorderbusiness.industryMiddle AgedOxindolesProlactinchemistryDopamine receptorAnesthesiaDopamine AgonistsAutoreceptorAntidepressantFemaleNeurology (clinical)medicine.symptombusinessPsychologymedicine.drugPsychopharmacology
researchProduct

Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature.

2015

Importance BRAF inhibitors have been licensed for the therapy of BRAF-mutated melanoma. Recently, inflammatory skin lesions clinically resembling erythema nodosum have been reported as therapy side-effects that may lead to treatment discontinuation. Objective To identify and characterize cases with BRAF inhibitor-associated erythema nodosum-like inflammatory skin lesions and development of an algorithm for their management. Design and Setting Retrospective chart review of melanoma patients treated with BRAF inhibitors in 14 departments of Dermatology in Germany and Austria and PubMed search for cases in the literature. Results Sixteen patients were identified who developed erythema nodosum-…

AdultMaleProto-Oncogene Proteins B-rafmedicine.medical_specialtyIndolesErythemaBiopsyMedizinDermatology030207 dermatology & venereal diseases03 medical and health sciencesYoung Adult0302 clinical medicineErythema NodosumOximesmedicineHumansskin and connective tissue diseasesVemurafenibneoplasmsAgedRetrospective StudiesSkinTrametinibErythema nodosumSulfonamidesintegumentary systembusiness.industryMelanomaImidazolesDabrafenibMiddle Agedmedicine.diseaseDermatology3. Good healthInfectious DiseasesVemurafenib030220 oncology & carcinogenesisFemalemedicine.symptombusinessPanniculitisVasculitismedicine.drugJournal of the European Academy of Dermatology and Venereology : JEADV
researchProduct